Advanced Enzyme Technologies Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Advanced Enzyme Technologies wird ein jährliches Gewinn- und Umsatzwachstum von 22.4% bzw. 11.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16% betragen.
Wichtige Informationen
22.4%
Wachstumsrate der Gewinne
22.4%
EPS-Wachstumsrate
| Chemicals Gewinnwachstum | 18.9% |
| Wachstumsrate der Einnahmen | 11.7% |
| Zukünftige Eigenkapitalrendite | 16.0% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 17 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Oct 06Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Sep 26Our Take On The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES)
Sep 21Does Advanced Enzyme Technologies (NSE:ADVENZYMES) Have A Healthy Balance Sheet?
Sep 08Have Insiders Sold Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Recently?
Aug 26Why We're Not Concerned About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price
Aug 21Introducing Advanced Enzyme Technologies (NSE:ADVENZYMES), A Stock That Climbed 60% In The Last Year
Aug 20Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) P/E Is On The Mark
Aug 07Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2026 | 7,888 | 2,114 | 2,105 | 2,405 | 1 |
| 3/31/2025 | 7,014 | 1,797 | 2,892 | 3,192 | 1 |
| 3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
| 12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
| 9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
| 6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
| 3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
| 12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
| 9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
| 6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
| 3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
| 12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
| 9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
| 6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
| 3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
| 12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
| 9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
| 6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
| 3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
| 12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
| 9/30/2019 | 4,366 | 1,210 | 1,147 | 1,276 | N/A |
| 6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
| 3/31/2019 | 4,220 | 1,111 | 1,162 | 1,286 | N/A |
| 12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
| 9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
| 6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
| 3/31/2018 | 3,918 | 901 | 1,050 | 1,160 | N/A |
| 12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
| 9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
| 6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
| 3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
| 12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
| 9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
| 6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
| 3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
| 3/31/2015 | 2,233 | 510 | N/A | 537 | N/A |
| 3/31/2014 | 2,397 | 201 | N/A | 433 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ADVENZYMESDas prognostizierte Gewinnwachstum (22.4% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: ADVENZYMESDie Erträge des Unternehmens (22.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).
Hohe Wachstumserträge: ADVENZYMESEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ADVENZYMESDie Einnahmen des Unternehmens (11.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.6% pro Jahr).
Hohe Wachstumseinnahmen: ADVENZYMESDie Einnahmen des Unternehmens (11.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ADVENZYMESDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16%).